Bi-Specific MAbS Market Trends That Will Shape the Next Decade: Insights from Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific MAbs Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Bi-Specific MAbS Market Size By 2025?
The size of the bi-specific MAbS market has witnessed rapid expansion in the past few years. The estimation is that the market will surge from $7.83 billion in 2024 to $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. The surge experienced in the historical period is credited to the increased spending in healthcare, larger funding, and government-led initiatives.

How Big Is the Bi-Specific MAbS Market Size Expected to Grow by 2029?
The market size of bi-specific MAbS is projected to experience swift expansion in the coming years, with predictions of reaching "$14.89 billion by 2029", reflecting a compound annual growth rate (CAGR) of 13.3%. The growth anticipated in this period can be traced back to the escalating incidences of cancer, an aging demographic, and a surge in chronic ailments. Key trends for this projection period comprise a concentration on technological progression, product enhancement, the integration of artificial intelligence, allocation of funds to targeted and combination therapy, and forming strategic alliances.

View the full report here:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Key Market Drivers Powering Bi-Specific MAbS Market Expansion and Growth?
The rise in cancer and other chronic diseases is expected to fuel growth in the bispecific monoclonal antibodies market during the forecast period. These bispecific monoclonal antibodies are designed to treat a variety of conditions, including different types of cancer, infectious diseases, and disorders of the central nervous system and the immune system. They are believed to be more potent than regular monoclonal antibodies, as they target multiple tumor antigens in cells, hindering the advancement of cancer. For example, the Cancer Facts & Figures 2023 report by the American Cancer Society - a US-based volunteer health group - predicts that there will be approximately 609,820 deaths from cancer in the USA in 2023. Therefore, increases in chronic diseases, particularly cancer, are expected to boost demand for bispecific monoclonal antibodies due to their effectiveness in treating these conditions.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Long-Term Trends Will Define the Future of the Bi-Specific MAbS Market?
Bi-specific MAbs market companies are progressively focusing their investments on strategic initiatives like collaborations and partnerships. These initiatives aim to enhance both their product range and geographic reach. A strategic collaboration is the pooling of resources between at least two organizations with the goal of achieving mutual objectives. For instance, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical companies, agreed to an exclusive collaboration for the development of MGD024. This bispecific antibody targets CD123 and CD3, and it is developed utilizing MacroGenics' DART platform. Two other bispecific research programs are also part of this agreement. This collaboration provides Gilead with the exclusive option to license MGD024, which could potentially treat various hematologic malignancies, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS) included. The design of MGD024 aims to lessen cytokine-release syndrome (CRS) and enable intermittent dosing, thereby possibly resulting in an improved, more patient-friendly treatment and better clinical outcomes for those with AML and MDS.

What Are the Emerging Segments in the Bi-Specific MAbS Market?
The bi-specific mabs market covered in this report is segmented -

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:
1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3
2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3
3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)
4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X
5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET
6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A
7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Who Are the Global Leaders in the Bi-Specific MAbS Market?
Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Which are the Top Profitable Regional Markets for the Bi-Specific MAbS Industry?
North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.